Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Consolidated Net Income (2017 - 2026)

Cogent Biosciences' Consolidated Net Income history spans 10 years, with the latest figure at -$97.2 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 35.05% to -$97.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$347.0 million through Mar 2026, down 27.8% year-over-year, with the annual reading at -$321.7 million for FY2025, 24.78% down from the prior year.
  • Consolidated Net Income came in at -$97.2 million for Q1 2026, down from -$95.3 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$31.3 million in Q1 2022 to a low of -$97.2 million in Q1 2026.
  • The 5-year median for Consolidated Net Income is -$58.3 million (2024), against an average of -$59.7 million.
  • Year-over-year, Consolidated Net Income plummeted 147.03% in 2022 and then fell 14.57% in 2025.
  • Cogent Biosciences' Consolidated Net Income stood at -$41.6 million in 2022, then tumbled by 30.56% to -$54.4 million in 2023, then decreased by 28.55% to -$69.9 million in 2024, then tumbled by 36.39% to -$95.3 million in 2025, then decreased by 2.0% to -$97.2 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Consolidated Net Income are -$97.2 million (Q1 2026), -$95.3 million (Q4 2025), and -$80.9 million (Q3 2025).